ILMN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Illumina Inc (ILMN) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, positive news catalysts, and favorable technical indicators support this recommendation.
The technical indicators for ILMN are bullish. The MACD is positively expanding above zero, the RSI is neutral at 69.797, and the moving averages (SMA_5 > SMA_20 > SMA_200) indicate an uptrend. The stock is trading near its resistance level (R1: 132.194), suggesting potential for further upward movement.
Illumina's partnership with D3b to analyze 100,000 pediatric genomes is a significant step in advancing research in pediatric cancer and rare diseases.
Analysts view Roche's higher-than-expected pricing for its competing product as a near-term positive for Illumina.
Strong Q4 2025 financial results, including a 78.61% YoY increase in net income and an 84.75% YoY increase in EPS, highlight the company's growth potential.
Insider selling has increased significantly (287.98% over the last month), which could indicate reduced confidence from company insiders.
Hedge funds remain neutral, showing no significant buying interest.
In Q4 2025, Illumina reported a 4.98% YoY increase in revenue to $1.159 billion, a 78.61% YoY increase in net income to $334 million, and an 84.75% YoY increase in EPS to 2.18. However, gross margin slightly declined to 65.49% (-0.68% YoY).
Analyst sentiment is mixed but leans positive. Several firms have raised their price targets recently, with targets ranging from $120 to $170. Notably, Piper Sandler and Evercore ISI maintain Overweight and Outperform ratings, respectively, while UBS and Baird have Neutral ratings. Analysts highlight strong Q4 results and potential growth from new initiatives like NovaSeq X and the Billion Cell Atlas.
